Abstract
Menopause constitutes a sizable proportion of the adult woman's life, and it is reasonable to consider that most women will benefit from hormone-replacement therapy. Also, it is important to realize that cardiovascular disease is a major cause of morbidity and death in the menopausal patient. Two regimens of hormone-replacement therapy were evaluated in postmenopausal women with 0.625 mg of conjugated equine estrogen with either 2.5 or 5 mg of medroxyprogesterone acetate taken continuously for 52 weeks in 92 patients. The data demonstrated an improvement in menopausal symptoms, a beneficial effect in lipoprotein profiles, the establishment of an atrophic endometrium, and a marked decrease in vaginal bleeding after 13 weeks and a further decrease after 26 weeks. Ideally this regimen will offer better patient compliance and, if the favorable lipoprotein profiles offer protection to the cardiovascular system, the overall health of the American woman will be markedly affected.
| Original language | English |
|---|---|
| Pages (from-to) | 1534-1542 |
| Number of pages | 9 |
| Journal | American Journal of Obstetrics and Gynecology |
| Volume | 162 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1990 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Medicine(all)
- Obstetrics and Gynecology
Cite this
Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient. / Weinstein, Louis; Bewtra, Chhanda; Gallagher, John Christopher G.
In: American Journal of Obstetrics and Gynecology, Vol. 162, No. 6, 1990, p. 1534-1542.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of a continuous combined low-dose regimen of estrogen-progestin for treatment of the menopausal patient
AU - Weinstein, Louis
AU - Bewtra, Chhanda
AU - Gallagher, John Christopher G.
PY - 1990
Y1 - 1990
N2 - Menopause constitutes a sizable proportion of the adult woman's life, and it is reasonable to consider that most women will benefit from hormone-replacement therapy. Also, it is important to realize that cardiovascular disease is a major cause of morbidity and death in the menopausal patient. Two regimens of hormone-replacement therapy were evaluated in postmenopausal women with 0.625 mg of conjugated equine estrogen with either 2.5 or 5 mg of medroxyprogesterone acetate taken continuously for 52 weeks in 92 patients. The data demonstrated an improvement in menopausal symptoms, a beneficial effect in lipoprotein profiles, the establishment of an atrophic endometrium, and a marked decrease in vaginal bleeding after 13 weeks and a further decrease after 26 weeks. Ideally this regimen will offer better patient compliance and, if the favorable lipoprotein profiles offer protection to the cardiovascular system, the overall health of the American woman will be markedly affected.
AB - Menopause constitutes a sizable proportion of the adult woman's life, and it is reasonable to consider that most women will benefit from hormone-replacement therapy. Also, it is important to realize that cardiovascular disease is a major cause of morbidity and death in the menopausal patient. Two regimens of hormone-replacement therapy were evaluated in postmenopausal women with 0.625 mg of conjugated equine estrogen with either 2.5 or 5 mg of medroxyprogesterone acetate taken continuously for 52 weeks in 92 patients. The data demonstrated an improvement in menopausal symptoms, a beneficial effect in lipoprotein profiles, the establishment of an atrophic endometrium, and a marked decrease in vaginal bleeding after 13 weeks and a further decrease after 26 weeks. Ideally this regimen will offer better patient compliance and, if the favorable lipoprotein profiles offer protection to the cardiovascular system, the overall health of the American woman will be markedly affected.
UR - http://www.scopus.com/inward/record.url?scp=0025372654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025372654&partnerID=8YFLogxK
U2 - 10.1016/0002-9378(90)90917-V
DO - 10.1016/0002-9378(90)90917-V
M3 - Article
VL - 162
SP - 1534
EP - 1542
JO - American Journal of Obstetrics and Gynecology
JF - American Journal of Obstetrics and Gynecology
SN - 0002-9378
IS - 6
ER -